Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant/adjuvant darovasertib in localized uveal melanoma
2023-506683-14-00Phase 2Authorised
- Sponsor
- IDEAYA Biosciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of darovasertib in intraocular melanoma (3 cohorts), sponsored by IDEAYA Biosciences. Primary endpoints: Safety during neoadjuvant therapy, Cohort-specific local treatment benefit and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
darovasertib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2023-506683-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506683-14-00.